Amrutanjan Health Care
576.55
-2.65(-0.46%)
Market Cap₹1,666.84 Cr
PE Ratio29.37
IndustryHealthcare
Company Performance:
1D-0.46%
1M+11.40%
6M-19.39%
1Y-13.97%
5Y-9.13%
View Company Insightsright
More news about Amrutanjan Health Care
03Feb 26
Amrutanjan Health Care Q3 Results: EBITDA Grows to ₹252M, Margin Declines YoY
Amrutanjan Health Care's Q3 results show EBITDA growth to ₹252M from ₹234M year-over-year, but EBITDA margin compressed to 17.85% from 19.02%. The company achieved revenue growth to ₹1.4B and maintained net profit at ₹195M, with board meeting held on February 3, 2026, for results review and interim dividend consideration.
 no imag found
11Nov 25
Amrutanjan Health Care Reports 7.08% Revenue Growth in Q2, Driven by Strong Pain Management Segment
Amrutanjan Health Care's Q2 results show a 7.08% YoY increase in revenue to Rs. 117.70 crores. Profit before tax grew by 20.51% to Rs. 19.21 crores, while profit after tax rose 14.23% to Rs. 15.94 crores. The pain management segment was a key growth driver, with the overall pain category growing 16%. The company plans to launch premium sanitary pads, revive the JIFFY brand, and commission a new sanitary napkin plant by late Q4. Management highlighted efforts to increase chemist channel reach and focus on market penetration in P1 markets and development in P2 markets.
 no imag found
10Nov 25
Amrutanjan Health Care Sets November 18, 2025 as Record Date for First Interim Dividend
Amrutanjan Health Care Limited has set November 18, 2025, as the record date for its first interim dividend of Re. 1/- per share for FY 2025-26. The company's board approved unaudited financial results for Q2 and H1 FY 2025-26, showing a 7.08% increase in revenue from operations and an 18.36% rise in profit after tax compared to the same quarter last year. The board meeting, held on November 10, 2025, lasted from 12:00 PM to 4:30 PM.
 no imag found
10Nov 25
Amrutanjan Health Care Reports Robust Q2 Performance with 18.4% Profit Growth
Amrutanjan Health Care Limited announced robust Q2 FY2025-26 results. Net profit increased by 18.4% to ₹139.60 crore, while revenue grew 7.1% to ₹1,177.00 crore. EBITDA rose 21.5% to ₹165.20 crore, with EBITDA margin expanding by 166 bps to 14.04%. The company declared a first interim dividend of ₹1 per share, with November 18, 2025, set as the record date.
 no imag found
12Aug 25
Amrutanjan Health Care Reports 80% Profit Surge, Sets AGM Date
Amrutanjan Health Care Limited announced Q1 FY2026 results with an 80% increase in profit after tax to ₹831.12 lakhs. Revenue from operations rose 12.3% to ₹9,404.57 lakhs. EPS improved to ₹2.87. OTC Products remained the largest revenue contributor. The company scheduled its 88th AGM for September 23, 2025, set September 16 as the record date, and appointed M/s. SPNP & Associates as Secretarial Auditor for five years.
 no imag found
15May 25
Amrutanjan Health Care Reports Strong Q4 Results, Announces Dividend
Amrutanjan Health Care's Q4 financial results show significant growth. Revenue increased by 6.30% to ₹1.35 billion, while net profit rose by 11.13% to ₹151.80 million. EBITDA improved to ₹177.00 million with a margin of 13.07%. The company also announced a final dividend of ₹2.60 per equity share, reflecting confidence in its financial position and commitment to shareholder value.
 no imag found
Amrutanjan Health Care
576.55
-2.65
(-0.46%)
1 Year Returns:-13.97%
Industry Peers
Sun Pharmaceutical
1,620.40
(-3.55%)
Divis Laboratories
6,361.50
(-0.27%)
Torrent Pharmaceuticals
4,117.20
(-0.72%)
Dr Reddys Laboratories
1,317.10
(-1.04%)
Lupin
2,296.10
(-1.93%)
Cipla
1,295.00
(-0.83%)
Mankind Pharma
2,267.40
(-1.11%)
Zydus Life Science
927.40
(-2.00%)
Aurobindo Pharma
1,413.80
(-1.50%)
Glenmark Pharmaceuticals
2,299.50
(-1.52%)